April 11, 2013

Sanofi Pasteur’s New Quadrivalent Influenza Vaccine Accepted for Review for European Approval

The addition of a fourth influenza virus strain to the seasonal trivalent vaccine aims to increase protection against influenza

 

Sanofi Pasteur’s New Quadrivalent Influenza Vaccine Accepted for Review for European Approval
The addition of a fourth influenza virus strain to the seasonal trivalent vaccine aims to increase protection against influenza

Lyon, France – April 11, 2013 – Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that a decentralized marketing authorization application has been accepted for review in the European Union countries for a quadrivalent (four-strain) formulation of Vaxigrip® Sanofi Pasteur’s seasonal inactivated split-virion influenza vaccine produced at its facility in Val de Reuil, France. The file has been accepted for review by France’s Agence nationale de sécurité du medicament et des produits de santé (ANSM) as the regulatory agency for the “Reference Member State”, and by national regulatory agencies from the EU countries.